Glaukos Co. (NYSE:GKOS) Stock Holdings Trimmed by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. lowered its position in shares of Glaukos Co. (NYSE:GKOS) by 86.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 23,398 shares of the medical instruments supplier’s stock after selling 150,000 shares during the quarter. Adage Capital Partners GP L.L.C.’s holdings in Glaukos were worth $3,508,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. IFP Advisors Inc bought a new position in shares of Glaukos in the 4th quarter worth about $43,000. Asset Planning Inc acquired a new stake in Glaukos during the fourth quarter worth about $90,000. Picton Mahoney Asset Management bought a new position in Glaukos in the fourth quarter worth about $125,000. SBI Securities Co. Ltd. acquired a new position in Glaukos in the fourth quarter valued at approximately $153,000. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Glaukos by 275.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock valued at $164,000 after purchasing an additional 807 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Trading Down 0.2 %

NYSE:GKOS opened at $93.61 on Wednesday. The business’s 50-day simple moving average is $99.73 and its 200-day simple moving average is $129.65. Glaukos Co. has a fifty-two week low of $77.91 and a fifty-two week high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The stock has a market capitalization of $5.34 billion, a PE ratio of -32.62 and a beta of 0.88.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Sell-side analysts expect that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Alex R. Thurman sold 1,520 shares of the firm’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the transaction, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at $5,708,568.04. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GKOS shares. Piper Sandler reduced their price objective on Glaukos from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Tuesday, April 15th. Wells Fargo & Company upped their target price on Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Mizuho lowered their price objective on shares of Glaukos from $200.00 to $175.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 16th. Stifel Nicolaus boosted their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Finally, Needham & Company LLC upped their price objective on shares of Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $156.17.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.